sirolimus intravitreal (Pending FDA Approval)

Brand and Other Names:
  • Print
Sections

Dosing & Uses

Uveitis

Pending FDA approval for noninfectious uveitis of the posterior segment (NIU-PS)

Next:

Pharmacology

Mechanism of Action

Intravitreal sirolimus inhibits the protein kinase that plays a critical role in inflammation

Immunoregulation is impacted by interrupting the inflammatory cascade by inhibiting T-cell activation, differentiation, and proliferation, and also by promoting immune tolerance, which thereby increases regulatory T lymphocytes

Previous
Next:

Images

No images available for this drug.
Previous
Next:

Patient Handout

A Patient Handout is not currently available for this monograph.
Previous
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.